Jan 7 (Reuters) - Solid Biosciences Inc SLDB.O:
SOLID BIOSCIENCES ANNOUNCES FDA IND CLEARANCE FOR FIRST-IN-INDUSTRY DUAL ROUTE OF ADMINISTRATION GENE THERAPY TO TREAT BOTH NEUROLOGIC AND CARDIAC MANIFESTATIONS OF FRIEDREICH’S ATAXIA
SOLID BIOSCIENCES INC: PHASE 1B CLINICAL TRIAL INITIATION EXPECTED IN 2H 2025
Source text: ID:nGNXbQwqFD
Further company coverage: SLDB.O
((Reuters.Briefs@thomsonreuters.com;))